Malaria with other antimalarials (known as artemisinin-combination therapy, or ACT), which decreases resistance to any single drug component. These additional antimalarials include: amodiaquine, lumefantrine, mefloquine or sulfadoxine/pyrimethamine. Another recommended combination is dihydroartemisinin and piperaquine. ACT is about 90% effective when used to treat uncomplicated malaria. To treat malaria during pregnancy, the WHO recommends the use of quinine plus clindamycin early in the pregnancy (1st trimester), and ACT in later stages (2nd and 3rd trimesters). In the 2000s (decade), malaria with partial resistance to artemisins emerged in Southeast Asia. Infection with "P. vivax", "P. ovale" or "P. malariae" usually do not require
Diagnosis of malaria microscope and centrifuge that can be deployed to rural areas in the third world. "Plasmodium malariae" and "P. knowlesi" (which is the most common cause of malaria in South-east Asia) look very similar under the microscope. However, "P. knowlesi" parasitemia increases very fast and causes more severe disease than "P. malariae", so it is important to identify and treat infections quickly. Therefore, modern methods such as PCR (see "Molecular methods" below) or monoclonal antibody panels that can distinguish between the two should be used in this part of the world. For areas where microscopy is not available, or where laboratory